We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.81B
1-Year Est. Return 192.15%
This Fund
S&P 500
This Quarter Est. Return
+32.4%
1 Year Est. Return
+192.15%
3 Year Est. Return
+320.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$903M
AUM Growth
+$291M
Cap. Flow
+$102M
Cap. Flow %
11.32%
Top 10 Hldgs %
78.43%
Holding
34
New
4
Increased
10
Reduced
5
Closed
10

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$31.7M
2
MOR
MorphoSys AG American Depositary Shares
MOR
+$31.1M
3
IMGN
Immunogen Inc
IMGN
+$28.3M
4
COGT icon
Cogent Biosciences
COGT
+$27.9M
5
DVAX
Dynavax Technologies
DVAX
+$14.1M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$30.2M
2
PCVX icon
Vaxcyte
PCVX
+$15.6M
3
TSHA icon
Taysha Gene Therapies
TSHA
+$10.4M
4
CLDX icon
Celldex Therapeutics
CLDX
+$5.71M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$2.9M

Sector Composition

Rank Sector Weight
1 Healthcare 97.89%
2 Miscellaneous 2.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$47.3B
$150M 16.66%
2,400,000
-603,668
-20% -$30.2M
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.84B
$122M 13.55%
5,660,000
+2,060,000
+57% +$31.7M
CLDX icon
3
Celldex Therapeutics
CLDX
$3.12B
$119M 13.21%
3,005,904
-194,096
-6% -$5.71M
PCVX icon
4
Vaxcyte
PCVX
$9.1B
$63M 6.97%
1,002,407
-300,000
-23% -$15.6M
VERA icon
5
Vera Therapeutics
VERA
$2.59B
$56.1M 6.22%
3,650,339
+694,286
+23% +$8.82M
PTGX icon
6
Protagonist Therapeutics
PTGX
$9.43B
$46M 5.09%
2,004,875
+186,218
+10% +$3.26M
IMGN
7
DELISTED
Immunogen Inc
IMGN
$42.2M 4.67%
+1,422,503
New +$28.3M
MOR
8
DELISTED
MorphoSys AG American Depositary Shares
MOR
$41.9M 4.64%
+4,234,685
New +$31.1M
COGT icon
9
Cogent Biosciences
COGT
$6.03B
$34.4M 3.81%
5,854,766
+3,644,641
+165% +$27.9M
LQDA icon
10
Liquidia Corp
LQDA
$6.15B
$32.5M 3.6%
2,698,324
+698,324
+35% +$5.03M
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.55B
$27.6M 3.05%
4,600,000
+1,466,807
+47% +$8.5M
TSVT
12
DELISTED
2seventy bio
TSVT
$25.4M 2.82%
5,953,825
– –
DVAX
13
DELISTED
Dynavax Technologies
DVAX
$21.2M 2.35%
1,514,383
+1,014,383
+203% +$14.1M
WVE icon
14
Wave Life Sciences
WVE
$958M
$19.9M 2.2%
3,932,082
– –
CORT icon
15
PUT
Corcept Therapeutics
CORT
$12.1B
$19M 2.11%
+585,900
New +$16.1M
TVTX icon
16
Travere Therapeutics
TVTX
$6.15B
$18M 1.99%
2,000,000
+1,042,498
+109% +$7.59M
VRDN icon
17
Viridian Therapeutics
VRDN
$2.6B
$13.2M 1.47%
607,915
-91,766
-13% -$1.45M
AMRN
18
Amarin Corp
AMRN
$288M
$10.5M 1.16%
601,148
– –
SLRN
19
DELISTED
ACELYRIN
SLRN
$8.95M 0.99%
1,200,000
– –
STRO icon
20
Sutro Biopharma
STRO
$333M
$8.59M 0.95%
200,173
+44,905
+29% +$1.42M
BNR
21
Burning Rock Biotech
BNR
$126M
$8.09M 0.9%
869,443
+19,443
+2% +$179K
CRBU icon
22
Caribou Biosciences
CRBU
$168M
$6.12M 0.68%
1,068,527
– –
TYRA icon
23
Tyra Biosciences
TYRA
$1.71B
$4.71M 0.52%
+340,190
New +$4.4M
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
$3.52M 0.39%
442,704
-287,768
-39% -$1.93M
CNTB
25
Connect Biopharma Holdings
CNTB
$116M
– –
-535,005
Closed -$434K
1
2

Similar funds

AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.81B AUM 52.11% 1-Year Est. Return
LPT
Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return
SFG
Sage Financial Group W. Conshohocken, Pennsylvania $1.81B AUM 22.3% 1-Year Est. Return
GA
Greenspring Advisors Towson, Maryland $1.8B AUM 22.29% 1-Year Est. Return
CCS
Concentric Capital Strategies Stamford, Connecticut $1.8B AUM 51.77% 1-Year Est. Return
PPW
Parcion Private Wealth Bellevue, Washington $1.8B AUM 30.57% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.8B AUM 22.23% 1-Year Est. Return

Kynam Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Kynam Capital Management held 34 positions worth $903M, up 48% from $611M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Kynam Capital Management deployed $102M of net new capital in Q4 2023, opening 4 new positions and adding to 10 existing holdings. Its largest new stake was MorphoSys AG American Depositary Shares: 4,234,685 shares worth $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Natera, an estimated $30.2M trimmed.

  • Kynam Capital Management's largest Q4 2023 buy was MorphoSys AG American Depositary Shares: 4,234,685 shares worth $41.9M.
  • Kynam Capital Management added most to Syndax Pharmaceuticals in Q4 2023, an estimated $31.7M increase.
  • Kynam Capital Management's biggest Q4 2023 reduction was Natera, cutting an estimated $30.2M.
  • Kynam Capital Management fully exited Taysha Gene Therapies in Q4 2023, selling an estimated $10.4M.
  • Kynam Capital Management's ten largest holdings make up 78% of its $903M portfolio in Q4 2023.
  • Kynam Capital Management opened 4 new positions and closed 10 in Q4 2023.
  • Kynam Capital Management's portfolio value rose 48% quarter-over-quarter to $903M.

Based on Kynam Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.